Replies to post #194297 on Biotech Values

[ronpopeil]

Management seems to believe the growth story is just starting.

[DewDiligence]

I don’t buy the MCUJF growth thesis. The bump from $15M to $30M will be the last “double” they achieve, IMO.

However, if I'm wrong and Aggrastat sales actually do reach $60M, then generics will likely enter the market in the next few years. The last CoM patent in the Orange Book expires in Oct 2016, and the three later-expiring patents are “use” patents that don’t seem capable of blocking a generic (http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020913&Product_No=002&table1=OB_Rx ).

[DewDiligence]

MCUJF submits sNDA for Aggrastat:

http://finance.yahoo.com/news/medicure-announces-filing-snda-aggrastat-155400397.html

I seriously doubt that an expanded label will make a material difference in sales.